

Advancing Research & Treatment for Frontotemporal Lobar Degeneration

Journal Articles

1. Lee SE, Khazenzon AM, Trujillo AJ, et al. Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. *Brain*. Nov 2014;137(Pt 11):3047-3060. PMID: 25273996, PMCID: PMC4208465
2. Sha SJ, Ghosh PM, Lee SE, et al. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. *Alzheimers Res. Ther.* 2015;7(1):8. PMID: 25733984, PMCID: PMC4346122
3. Finger EC, MacKinley J, Blair M, et al. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. *Neurology*. Jan 13 2015;84(2):174-181. PMID: 25503617, PMCID: PMC4336088
4. Fiandaca MS, Kapogiannis D, Mapstone M, et al. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. Jun 2015;11(6):600-607 e601. PMID: 25130657, PMCID: PMC4329112
5. Iglesias JE, Van Leemput K, Bhatt P, et al. Bayesian segmentation of brainstem structures in MRI. *Neuroimage*. Jun 2015;113:184-195. PMID: 25776214, PMCID: PMC4434226
6. Block NR, Sha SJ, Karydas AM, et al. Frontotemporal Dementia and Psychiatric Illness: Emerging Clinical and Biological Links in Gene Carriers. *Am. J. Geriatr. Psychiatry*. Jun 21 2015. PMID: 26324540
7. McCarter SJ, Tippmann-Peikert M, Sandness DJ, et al. Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. *Sleep medicine*. Dec 2015;16(12):1502-1510. PMID: 26611948
8. Boman A, Svensson S, Boxer A, et al. Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid. *Journal of Parkinson's disease*. 2016;6(2):307-315. PMID: 27061067, PMCID: PMC4927933
9. Dutt S, Binney RJ, Heuer HW, et al. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. *Neurology*. 2016;87(19):2016-2025. PMID: 27742814, PMCID: PMC5109951
10. Espay AJ, Bonato P, Nahab FB, et al. Technology in Parkinson's disease: Challenges and opportunities. *Mov Disord*. 2016;31(9):1272-1282. PMID: 27125836, PMCID: PMC5014594
11. Goetzl EJ, Kapogiannis D, Schwartz JB, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease. *FASEB J*. 2016;30(12):4141-4148. PMID: 27601437, PMCID: PMC5102122

12. Hewer S, Varley S, Boxer AL, Paul E, Williams DR. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale. *Mov Disord*. 2016;31(10):1574-1577. PMID: 27324431, PMCID: PMC5215805
13. Litvan I, Lees PS, Cunningham CR, et al. Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. *Mov Disord*. 2016;31(5):644-652. PMID: 26854325, PMCID: PMC4861658
14. Miller ZA, Sturm VE, Camsari GB, et al. Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: Completing the picture. *Neurology(R) neuroimmunology & neuroinflammation*. 2016;3(6):e301. PMID: 27844039, PMCID: PMC5087253
15. Nandipati S, Litvan I. Environmental Exposures and Parkinson's Disease. *Int J Environ Res Public Health*. 2016;13(9). PMID: 27598189, PMCID: PMC5036714
16. Onyike CU. Psychiatric Aspects of Dementia. *Continuum (Minneapolis, Minn)*. 2016;22(2 Dementia):600-614. PMID: 27042910
17. Santos-Santos MA, Mandelli ML, Binney RJ, et al. Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. *JAMA neurology*. 2016;73(6):733-742. PMID: 27111692, PMCID: PMC4924620
18. Stamelou M, Schope J, Wagenpfeil S, et al. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. *Mov Disord*. 2016;31(5):742-747. PMID: 26948290, PMCID: PMC5289149
19. Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. *J Neurochem*. 2016;138 Suppl 1:211-221. PMID: 27306957, PMCID: PMC5217534
20. Walsh CM, Ruoff L, Varbel J, et al. Rest-activity rhythm disruption in progressive supranuclear palsy. *Sleep medicine*. 2016;22:50-56. PMID: 27544836, PMCID: PMC4996365
21. Zhang Y, Walter R, Ng P, et al. Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. *PLoS ONE*. 2016;11(6):e0157218. PMID: 27310132, PMCID: PMC4911077
22. Rojas JC, Boxer AL. Neurodegenerative disease in 2015: Targeting tauopathies for therapeutic translation. *Nature reviews. Neurology*. Feb 2016;12(2):74-76. PMID: 26794651
23. Bang J, Lobach IV, Lang AE, et al. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. *Parkinsonism Relat. Disord*. Apr 18 2016. PMID: 27172829
24. Tsai RM, Lobach I, Bang J, et al. Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. *Parkinsonism Relat. Disord*. Apr 24 2016. PMID: 27132501
25. Besser LM, Litvan I, Monsell SE, et al. Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease. *Parkinsonism Relat Disord*. Jun 2016;27:54-60. PMID: 27089852, PMCID: PMC4887313

26. Bejanin A, Schonhaut DR, La Joie R, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. *Brain*. 2017;140(12):3286-3300. PMID: 29053874
27. Chen J, Yu JT, Wojta K, et al. Genome-wide association study identifies MAPT locus influencing human plasma tau levels. *Neurology*. 2017;88(7):669-676. PMID: 28100725, PMCID: PMC5317386
28. Fernandez-Fournier M, Perry DC, Tartaglia MC, et al. Precipitous Deterioration of Motor Function, Cognition, and Behavior. *JAMA neurology*. 2017;74(5):591-596. PMID: 28264087
29. Gendron TF, Chew J, Stankowski JN, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. *Sci Transl Med*. 2017;9(383). PMID: 28356511
30. Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Mov Disord*. 2017. PMID: 28467028
31. Hoglinger GU, Schope J, Stamelou M, et al. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. *Mov Disord*. 2017. PMID: 28436538
32. Lopez A, Lee SE, Wojta K, et al. A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. *Brain*. 2017;140(4):1128-1146. PMID: 28334843, PMCID: PMC5382950
33. Perry DC, Brown JA, Possin KL, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. *Brain*. 2017;140(12):3329-3345. PMID: 29053860
34. Roe CM, Barco PP, Head DM, et al. Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. *Alzheimer Dis Assoc Disord*. 2017;31(1):69-72. PMID: 27128959, PMCID: PMC5085874
35. Scherling CS, Zakrzewski J, Datta S, et al. Mistakes, Too Few to Mention? Impaired Self-conscious Emotional Processing of Errors in the Behavioral Variant of Frontotemporal Dementia. *Frontiers in behavioral neuroscience*. 2017;11:189. PMID: 29089874, PMCID: PMC5651000
36. Schonhaut DR, McMillan CT, Spina S, et al. 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. *Ann Neurol*. 2017;82(4):622-634. PMID: 28980714, PMCID: PMC5665658
37. Seo SW, Ayakta N, Grinberg LT, et al. Regional correlations between [(11)C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. *NeuroImage Clinical*. 2017;13:130-137. PMID: 27981028, PMCID: PMC5144753
38. Sha SJ, Miller ZA, Min SW, et al. An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. *Alzheimer's & dementia (New York, N Y)*. 2017;3(4):507-512. PMID: 29124108, PMCID: PMC5671622
39. Spina S, Schonhaut DR, Boeve BF, et al. Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations. *Neurology*. 2017;88(8):758-766. PMID: 28130473, PMCID: PMC5344079

40. Spinelli EG, Mandelli ML, Miller ZA, et al. Typical and atypical pathology in primary progressive aphasia variants. *Ann Neurol.* 2017;81(3):430-443. PMID: 28133816, PMCID: PMC5421819

Yokoyama JS, Karch CM, Fan CC, et al. Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. *Acta Neuropathol.* 2017;133(5):825-837. PMID: 28271184, PMCID: PMC5429027